Xiaowen Feng
About Xiaowen Feng
Xiaowen Feng is a Co-Founder and Director on the Board of Directors at META Pharmaceuticals Inc. and has extensive experience in the biotech sector, including roles at Kula Bio and Regenerative Bio Inc.
Work at Kula
Xiaowen Feng serves as Co-Founder at Kula Bio, a position he has held since 2018. The company is based in Boston, Massachusetts, and focuses on innovative solutions in the biotechnology sector. His role involves strategic planning and operational oversight, contributing to the company's mission of advancing sustainable agricultural practices through biotechnology.
Current Roles in Biotechnology
In addition to his role at Kula Bio, Xiaowen Feng is actively involved in several other organizations. He has been a Director on the Board of Directors at META Pharmaceuticals Inc. since 2021 in Shenzhen, Guangdong, China. He also holds the position of Chief Strategy Officer and Director on the Board of Directors at Regenerative Bio Inc. since 2020 in Hangzhou, Zhejiang, China. Furthermore, he became a Director on the Board of Directors at PixelBiotech GmbH in 2023.
Education and Expertise
Xiaowen Feng earned his Bachelor of Science in Chemistry from Peking University, completing his studies from 2005 to 2009. He further advanced his education by obtaining a Doctor of Philosophy in Chemistry from the University of California, Berkeley, where he studied from 2009 to 2015. His academic background provides a strong foundation for his work in biotechnology and medical applications.
Previous Experience at Harvard University
Xiaowen Feng worked as a Postdoctoral Researcher at Harvard University from 2015 to 2019. During this time, he engaged in advanced research, contributing to the academic community and enhancing his expertise in the field of biological sciences. This experience has informed his subsequent roles in the biotechnology industry.
Venture Capital Involvement
Xiaowen Feng co-founded Forcefield Ventures, a venture capital firm that focuses on supporting biotech companies. He has been a Venture Partner at IMO Ventures since 2018, where he plays a role in financial investment and resource allocation to foster the growth of biotech companies within the portfolio ecosystem.